PharmiNews

The Directory of Pharma Companies and News

Oxford BioTherapeutics

Oxford BioTherapeutics logo
Oxford BioTherapeutics is an international, clinical-stage biotechnology company developing antibody therapeutics for cancer. Combining next generation immuno-oncology, ADC* and fully human monoclonal antibody approaches against novel human tumor cell membrane-derived checkpoint targets identified using its unique target selection and validation platform, the Company has gathered compelling in vivo evidence of the potency of its broad pipeline.
Category: Biotech
Category: Biotech

Oxford BioTherapeutics News

DateNews
2016-04-04Oxford BioTherapeutics Licenses Nerviano Medical Sciences’ Drug-Linker Technology to Develop Novel Antibody Drug Conjuga... (PDF)
2015-08-10Oxford BioTherapeutics Appoints Shawn Tomasello to its Board of Directors (PDF)
2014-08-07Oxford BioTherapeutics Appoints Eugen Leo MD PhD MBA as Head of Clinical Development (PDF)
2014-07-05Oxford BioTherapeutics Takes Exclusive Rights to Use Amgen Xenomouse® Antibodies and ImmunoGen Technology to Develop Nov... (PDF)
2014-02-10Oxford BioTherapeutics and Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate as Second Clinical Development ... (PDF)
2013-09-12Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia as First Clinical Development ... (PDF)
2012-11-01Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director (PDF)
2012-02-05Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzer... (PDF)
-0001-11-30Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics (PDF)
-0001-11-30Boehringer Ingelheim exercises option on second oncology target using Oxford BioTherapeutics’ OGAP® system (PDF)
-0001-11-30Oxford BioTherapeutics receives $10 million capital term loan from Silicon Valley Bank (PDF)
-0001-11-30Oxford BioTherapeutics to Present at 35th Cowen and Company Annual Health Care Conference in Boston (PDF)
-0001-11-30Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim for Development and Commercialization of Anti... (PDF)
-0001-11-30$1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics Initiates First-in-Human Study of Enhanced ... (PDF)
-0001-11-30Oxford BioTherapeutics Appoints Dr Keith E Wilson as Chief Scientific Officer (PDF)
-0001-11-30Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors (PDF)
-0001-11-30Oxford BioTherapeutics Appoints Bryan G. Morton as Chairman (PDF)
-0001-11-30Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer (PDF)
-0001-11-30Menarini Group and Oxford BioTherapeutics Collaborate for Development and Manufacture of Novel Antibody-Based Cancer Dru... (PDF)
-0001-11-30Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.